Abstract 651P
Background
XNW27011 is a novel claudin 18.2(CLDN 18.2)-targeting ADC with the TMALIN® linker, a proprietary TOP1i payload more potent than Dxd, and homogeneous DAR of 8. Here we report the preliminary results from the dose escalation phase of the first in human, multi-center, open-label, phase I/II study of XNW27011 in patients (pts) with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies.
Methods
XNW27011 was given starting from 0.6 mg/kg (Q3W, IV) in an accelerated titration followed by 3+3 escalation scheme. The primary objective of dose escalation phase was to determine MTD.
Results
As of Apr. 15, 2024, 16 pts were enrolled in 6 dose cohorts from 0.6 to 6.0 mg/kg, including 11 GC/GEJC, 2 OC, 2 PC, and 1 duodenal periampullary adenocarcinoma (ECOG 0-1, majority of pts received ≥3 lines of prior therapy). 12 pts had various levels of CLDN18.2-expression (≥1%, IHC ≥ 1+). During DLT period, the most common AEs were nausea and vomiting, followed by white blood cell decrease, neutrophil decrease and anemia. No ≥ grade 3 TRAEs were observed below 4.8 mg/kg during DLT period. No ILD or MMAE-related ocular AEs and peripheral neuropathy were observed. One patient experienced DLT at 6.0 mg/kg. The table summarized efficacy in 14 evaluable pts. Efficacy was observed even at doses as low as 0.6 mg/kg. Prior PD-1 immunotherapy, irinotecan or CLDN18.2 antibody therapy seemed not to impact efficacy. Table: 651P
Efficacy outcomes
All tumor (n=14) | CLDN18.2+ * tumor (n=11) | CLDN18.2+ * GC/GEJC 1 (n=8) | CLDN18.2+ * OC 2 (n=2) | CLDN18.2+ * PC 3 (n=1) | |
ORR | 50% (7/14) | 64% (7/11) | 63% (5/8) | 50% (1/2) | 100% (1/1) |
DCR | 86% (12/14) | 100% (11/11) | 100% (8/8) | 100% (2/2) | 100% (1/1) |
*CLDN18.2+: any level of CLDN18.2 expression, defined as CLDN 18.2 _1%, IHC_1+; GC/GEJC1: gastric cancer/gastroesophageal junction cancer; OC2: ovarian cancer; PC3: pancreatic cancer
XNW27011 has shown similar concentration-time curves of ADC and TAb, long T1/2= 5-9 days, and extremely low free payload at all tested doses (Cmax of 0.253 to 1.65 ng/mL corresponding to 0.6-6.0 mg/kg doses).
Conclusions
XNW27011 demonstrated a favorable safety profile with large therapeutic window, superior preliminary efficacy across tumor type and CLDN 18.2 expression level, and excellent PK properties including low payload plasma exposure. The study is ongoing with the expansion phase being initiated in multiple tumor cohorts.
Clinical trial identification
Editorial acknowledgement
Xiujing Emma Feng from Evopoint Biosciences USA, Inc.
Legal entity responsible for the study
Evopoint Biosciences Co. Ltd.
Funding
Evopoint Biosciences Co. Ltd.
Disclosure
H. Zhao, Y. Hu, H. Wei, Y. Zhao, Y. Wang, Q. Shi, J. Li: Financial Interests, Personal, Full or part-time Employment: Evopoint Biosciences Co. Ltd.; Financial Interests, Personal, Stocks/Shares: Evopoint Biosciences Co. Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01